NCT05688176 Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers
| NCT ID | NCT05688176 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Ghent |
| Condition | Esophageal Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2016-06 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2016-06 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is designed to perform a explorative search of the transcriptome to detect new circulating diagnostic sensitive and specific biomarkers in patients with Barrett's esophagus or esophageal adenocarcinoma.
Eligibility Criteria
Inclusion Criteria: * Barrett's Esophagus with length \> 3cm OR esophageal adenocarcinoma histologically proven * Adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent * Age over 18 years * No other concurrent malignant disease * No inclusion in other clinical trials interfering with the study protocol * No concurrent chronic systemic immune or hormone therapy, except neoadjuvant chemotherapy * Absence of any severe organ insufficiency * No pregnancy or breast feeding * Written informed consent Exclusion Criteria: * Pregnancy or breast feeding * Active bacterial, viral or fungal infection * Parenchymal liver disease (any stage cirrhosis) * High risk of bleeding during biopsy (anticoagulants, esophageal varices) * Esophageal squamous cell carcinoma * Helicobacter pylori positive at the time of biopsy sampling * Radiofrequency ablation of the oesophagus * Psychiatric pathology capable of affecting comprehension and judgement faculty
Contact & Investigator
Piet Pattyn, MD, PhD
PRINCIPAL INVESTIGATOR
University Hospital, Ghent
Frequently Asked Questions
Who can join the NCT05688176 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05688176 currently recruiting?
Yes, NCT05688176 is actively recruiting participants. Contact the research team at piet.pattyn@ugent.be for enrollment information.
Where is the NCT05688176 trial being conducted?
This trial is being conducted at Ghent, Belgium.
Who is sponsoring the NCT05688176 clinical trial?
NCT05688176 is sponsored by University Hospital, Ghent. The principal investigator is Piet Pattyn, MD, PhD at University Hospital, Ghent. The trial plans to enroll 100 participants.